Genetic determinants of the response to bezafibrate treatment in the lower extremity arterial disease event reduction (LEADER) trial

Atherosclerosis

Volumn 163, Issue 1, 2002, Pages 183-192

  Jamshidi, Y ^a   Flavell, D M ^a   Hawe, E ^a   MacCallum, P K ^b   Meade, T W ^b   Humphries, S E ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Apolipoprotein CIII; Bezafibrate; Fibrinogen; Gene polymorphism; Peroxisome proliferator activated receptor ; Triglycerides

Indexed keywords

APOLIPOPROTEIN; BEZAFIBRATE; FIBRINOGEN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; TRIACYLGLYCEROL; ANTILIPEMIC AGENT; APOLIPOPROTEIN C; APOLIPOPROTEIN C3;

ADULT; AGED; ARTERY DISEASE; ARTICLE; CIGARETTE SMOKING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DNA POLYMORPHISM; DOUBLE BLIND PROCEDURE; FEMALE; FIBRINOGEN BLOOD LEVEL; GENE FREQUENCY; GENE INTERACTION; GENE LINKAGE DISEQUILIBRIUM; HETEROZYGOTE; HUMAN; INTRON; LEG DISEASE; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; PRIORITY JOURNAL; TRIACYLGLYCEROL BLOOD LEVEL; ANALYSIS OF VARIANCE; BLOOD; COMPARATIVE STUDY; DOSE RESPONSE; DRUG ADMINISTRATION; FOLLOW UP; GENETIC MARKER; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETICS; GENOTYPE; MIDDLE AGED; MOLECULAR GENETICS; NUCLEOTIDE SEQUENCE; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PERIPHERAL VASCULAR DISEASE; POLYMERASE CHAIN REACTION; PROBABILITY; RANDOMIZED CONTROLLED TRIAL; REFERENCE VALUE; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; ANTILIPEMIC AGENTS; APOLIPOPROTEIN C-III; APOLIPOPROTEINS C; ARTERIAL OCCLUSIVE DISEASES; BASE SEQUENCE; BEZAFIBRATE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; FIBRINOGEN; FOLLOW-UP STUDIES; GENETIC MARKERS; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; PERIPHERAL VASCULAR DISEASES; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; PROBABILITY; REFERENCE VALUES; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME;

EID: 0036016002     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0021-9150(02)00002-3     Document Type: Article

References (65)

1. Femoral atherosclerosis in an older British population: Prevalence and risk factors
2. Lower extremity arterial disease and the aging process: A review
3. Intermittent claudication in Quebec men from 1974-1986: The Quebec Cardiovascular Study
4. Update on some epidemiologic features of intermittent claudication: The Framingham Study
5. Diabetes, intermittent claudication, and risk of cardiovascular events. The Framingham Study
6. A marked decline in the prevalence and incidence of intermittent claudication in Icelandic men 1968-1986: A strong relationship to smoking and serum cholesterol - The Reykjavik Study
7. Prevalence of intermittent claudication and its effect on mortality
8. Intermittent claudication: Prevalence and risk factors
9. Role of systolic blood pressure and plasma triglycerides in diabetic peripheral arterial disease. The Edinburgh Artery Study
10. Predictors of the presence and extent of peripheral arterial occlusive disease
11. Inter-relationships of plasma fibrinogen, low-density lipoprotein cholesterol, cigarette smoking and the prevalence of cardiovascular disease
12. Fibrinogen as a risk factor for stroke and myocardial infarction
13. Haemostatic function and ischaemic heart disease: Principal results of the Northwick Park Heart Study
14. Fibrinogen and risk of cardiovascular disease. The Framingham Study
15. Fibrinogen and factor VII in the prediction of coronary risk. Results from the PROCAM study in healthy men
16. Fibrinogen as a cardiovascular risk factor: A meta-analysis and review of the literature
17. Fibrinogen, viscosity and the 10-year incidence of ischaemic heart disease
18. Prospective study of hemostatic factors and incidence of coronary heart disease: The Atherosclerosis Risk in Communities (ARIC) Study
19. Haemostatic factors and prediction of ischaemic heart disease and stroke in claudicants
20. Fibrinogen and peripheral arterial disease
21. A six year prospective study of fibrinogen and other risk factors associated with mortality in stable claudicants
22. Associations of ankle-brachial index with clinical coronary heart disease, stroke and preclinical carotid and popliteal atherosclerosis: The Atherosclerosis Risk in Communities (ARIC) Study
23. Intermittent claudication in 8343 men and 21-year specific mortality follow-up
24. Intermittent claudication and subsequent cardiovascular disease in the elderly
25. Mortality over a period of 10 years in patients with peripheral arterial disease
26. Intermittent claudication, heart disease risk factors, and mortality. The Whitehall Study
27. Fate of the patient with chronic leg ischaemia. A review article
28. The peroxisome proliferator activated receptors (PPARS) and their effects on lipid metabolism and adipocyte differentiation
29. Differential expression of peroxisome proliferator-activated receptors (PPARs): Tissue distribution of PPAR-alpha, -beta, and -gamma in the adult rat
30. Expression of peroxisome proliferator-activated receptor alpha (PPAR alpha) in primary cultures of human vascular endothelial cells
31. Activation of human aortic smooth-muscle cells is inhibited by PPARalpha but not by PPARgamma activators
32. Activation of proliferator-activated receptors alpha and gamma induces apoptosis of human monocyte-derived macrophages
33. Fibrates downregulate apolipoprotein C-III expression independent of induction of peroxisomal acyl coenzyme A oxidase. A potential mechanism for the hypolipidemic action of fibrates
34. PPARalpha and PPARgamma activators direct a distinct tissue-specific transcriptional response via a PPRE in the lipoprotein lipase gene
35. Negative regulation of the human apolipoprotein A-I promoter by fibrates can be attenuated by the interaction of the peroxisome proliferator-activated receptor with its response element
36. Fibrates increase human apolipoprotein A-II expression through activation of the peroxisome proliferator-activated receptor
37. Baseline characteristics of patients participating in the Bezafibrate Infarction Prevention (BIP) Study
38. Bezafibrate lowers plasma lipids, fibrinogen and platelet aggregability in hypertriglyceridaemia
39. The fibrinolytic system and coagulation during bezafibrate treatment of hypertriglyceridemia
40. Bezafibrate retard in patients with insulin-dependent diabetes: Effect on serum lipoproteins, fibrinogen, and glycemic control
41. Bezafibrate. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hyperlipidaemia
42. Developmental and pharmacological regulation of apolipoprotein C-II gene expression. Comparison with apo C-I and apo C-III gene regulation
43. Transcriptional control of triglyceride metabolism: Fibrates and fatty acids change the expression of the LPL and apo C-III genes by activating the nuclear receptor PPAR
44. The nuclear receptors peroxisome proliferator-activated receptor alpha and Rev-erbalpha mediate the species-specific regulation of apolipoprotein A-I expression by fibrates
45. Regulation of apo A-I gene expression by fibrates
46. Opposite regulation of human versus mouse apolipoprotein A-I by fibrates in human apolipoprotein A-I transgenic mice
47. Fibrates suppress fibrinogen gene expression in rodents via activation of the peroxisome proliferator-activated receptor-alpha
48. Fibrate-modulated expression of fibrinogen, plasminogen activator inhibitor-1 and apolipoprotein A-I in cultured cynomolgus monkey hepatocytes - Role of the peroxisome proliferator-activated receptor-alpha
49. Design and intermediate results of the LEADER trial of bezafibrate in men with lower extremity arterial disease
50. A simple salting out procedure for extracting DNA from human nucleated cells
51. Variation in the PPARalpha gene is associated with altered function in vitro and plasma lipid concentrations in Type II diabetic subjects
52. Electrophoresis for genotyping: Microtiter array diagonal gel electrophoresis on horizontal polyacrylamide gels, hydrolink, or agarose
53. Association of genetic variation at the beta-fibrinogen gene locus and plasma fibrinogen levels; Interaction between allele frequency of the G/A-455 polymorphism, age and smoking
54. Contribution of apolipoprotein C-III gene variants to determination of triglyceride levels and interaction with smoking in middle-aged men
55. ApoCIII gene variants modulate postprandial response to both glucose and fat tolerance tests
56. Lowering fibrinogen levels: Clinical update. BIP Study Group. Bezafibrate Infarction Prevention
57. Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients
58. Rationale and design of a secondary prevention trial of increasing serum high-density lipoprotein cholesterol and reducing triglycerides in patients with clinically manifest atherosclerotic heart disease (the Bezafibrate Infarction Prevention Trial)
59. The human peroxisome proliferator-activated receptor alpha gene: Identification and functional characterization of two natural allelic variants
60. Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors alpha and delta
61. Evidence for direct binding of fatty acids and eicosanoids to human peroxisome proliferators-activated receptor alpha
62. Differential activation of peroxisome proliferator-activated receptors by eicosanoids
63. Common genetic variation in the promoter of the human apo CIII gene abolishes regulation by insulin and may contribute to hypertriglyceridemia
64. A common mutation (G-455→A) in the beta-fibrinogen promoter is an independent predictor of plasma fibrinogen, but not of ischemic heart disease. A study of 9,127 individuals based on the Copenhagen City Heart Study
65. Gene-environment interaction in the determination of levels of haemostatic variables involved in thrombosis and fibrinolysis